The news: The FDA is proposing changes to its rare disease drug review framework to give drugmakers clearer expectations around the data and evidence needed for approvals. It will also give patients a greater role in drug development. The agency will hold a public meeting on October 28 to gather input from patients, advocates, researchers, and drug developers and plans to release initial recommendations by February, per Bloomberg.

Why it matters: The FDA's proposed changes come as drugmakers raise concerns about conflicting agency guidance following a series of unexpected rare disease drug rejections. For example, the FDA blocked uniQure f from submitting an application for its Huntington’s disease treatment. The company said the FDA had reversed written guidance around UniQure’s clinical data and didn’t share the criticisms then-FDA Director Marty Makary made on CNBC, per STAT.

Drugmakers could get clearer guidance through the review process, making the pathway more predictable. The FDA says it plans to provide more tailored feedback, communicate its decisions more clearly, develop shared resources and training for rare disease reviews, and bring in outside experts to help evaluate treatments. That could help them better understand what evidence the FDA expects and reduce the risk of unexpected rejections.

Patients could also have a more defined role in drug development. The FDA wants to incorporate patient input earlier and at specific points throughout development and review, rather than primarily near the end of the process. That could give patients greater influence over how treatments are evaluated and improve the chances that approved therapies address the symptoms and outcomes that matter most to them.

Implications for pharma marketers: Small patient populations and limited clinical evidence make consistent FDA guidance especially valuable in rare disease development. Drugmakers can help shape that guidance by weighing in on the proposed framework, particularly on how the FDA evaluates evidence and incorporates patient input.

While many rare disease drugmakers already work closely with patient advocacy groups, the proposed changes could require a more structured approach to that engagement. Companies may need to show how patient input shapes decisions about clinical trials, acceptable risks, and meaningful treatment benefits throughout development.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.